Wegovy® (semaglutide 2.4mg) by Novo Nordisk is now Available in Singapore for Weight Management
The once-weekly injectable supports weight loss when used alongside a reduced-calorie diet and increased physical activity.
The launch marks a step toward evidence-based, compassionate treatment of obesity as a chronic disease—not a personal failing.
References:
Wegovy Singapore Prescribing Information, February 2025 Cuciureanu M, Caratașu CC, Gabrielian L, Frăsinariu OE, Checheriță LE, Trandafir LM, Stanciu GD, Szilagyi A, Pogonea I, Bordeianu G, Soroceanu RP, Andrițoiu CV, Anghel MM, Munteanu D, Cernescu IT, Tamba BI. 360-Degree Perspectives on Obesity. Medicina (Kaunas). 2023 Jun 9;59(6):1119. doi: 10.3390/medicina59061119. PMID: 37374323; PMCID: PMC10304508. World Obesity. Retrieved from https://www.worldobesity.org/about/about-obesity/prevalence-of-obesity World Obesity. Retrieved from https://data.worldobesity.org/country/singapore-192/ Scott I. Kahan, MD, MPH. Practical Strategies for Engaging Individuals With Obesity in Primary Care. Mayo Clin Proc. 2018;93(3):351-359 2. CDC, Cancers Associated with Overweight and Obesity Makeup 40 percent of Cancers Diagnosed in the United States. Available at https://www.cdc.gov/media/releases/2017/p1003-vs-cancer-obesity.html. World Health Organization. (2024). Obesity and overweight.WHO.https://www.who.int/news-room/factsheets/detail/obesity-and-overweight As accessed on 22nd May 2025. Leu J, Rebello SA, Sargent GM, Kelly M, Banwell C. Hard work, long hours, and Singaporean young adults' health. A qualitative study. Frontiers in Public Health. 2023; 11. https://doi.org/10.3389/fpubh.2023.1082581
SINGAPORE - Media OutReach Newswire - 12 July 2025 - A significant advancement in weight management has arrived for Singaporeans. Novo Nordisk, a global healthcare company focused on defeating serious chronic diseases, has announced the availability of Wegovy(semaglutide 2.4mg) in Singapore.Wegovy® (semaglutide 2.4mg) is a once-weekly injectable treatment indicated for chronic weight management in adults and adolescents (aged 12 and above) living with obesity (BMI ≥30 kg/m²), or who are overweight (BMI ≥27 kg/m² to <30 kg/m²) with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. It is used alongside a reduced-calorie diet and increased physical activity, supporting Singapore's efforts to improve population health.The treatment works by addressing one of the underlying biological drivers of obesity. Wegovy® (semaglutide 2.4mg) is a GLP-1 receptor agonist with 94% similarity to the body's natural GLP-1 hormone. It activates receptors involved in appetite regulation, helping individuals feel full sooner and reduce food intake. This mechanism supports weight loss when combined with sustainable lifestyle changes.The availability of Wegovy® (semaglutide 2.4mg) comes as obesity continues to pose a significant health burden in Singapore. An estimated 600,000 adults are currently living with obesity, a condition associated with more than 200 health complications. Despite its prevalence and medical complexity, obesity remains heavily stigmatised—often misunderstood as merely the result of poor personal choices. Individuals living with obesity frequently face discrimination and mental health challenges which further isolate them. This misplaced blame, rather than targeting the disease itself, creates barriers to and slows the advancement of effective obesity treatment. Recognised by World Health Organization as a chronic disease, obesity requires compassionate evidence-based care. The launch of Wegovy® (semaglutide 2.4mg) in Singapore provides a new treatment option for weight management available through private prescription.Dr Abel Soh, Abel Soh Diabetes, Thyroid and Endocrine Clinic and Chairperson for Endocrine and Metabolic Society of Singapore (EMSS) stated, "Obesity is not simply the result of lifestyle choices — it is a medically recognised chronic disease influenced by a complex interplay of genetics, hormones, and environment. In my clinical practice, I see firsthand how many individuals blame themselves when in fact, their biology is often working against them. It's time we shift the conversation from blame to support in the management of individuals with obesity"Lifestyle factors in Singapore further contribute to the challenge. In Singapore's demanding work culture—where full-time employees work an average of 44.6 hours per week, with time constraints and fatigue frequently cited as barriers to maintaining regular physical activity. These circumstances underscore the importance of comprehensive treatment strategies that facilitate the adoption of healthier lifestyles, including increased physical activity and a reduced-calorie diet, as integral components of long-term weight management.Mr Vincent Siow, General Manager, Novo Nordisk Singapore, said "With treatments like Wegovy(semaglutide 2.4mg) now available in Singapore, we have an opportunity to provide healthcare professionals with more evidence-based options to support their patients in regaining control of their health and improving long-term outcomes."Hashtag: #NovoNordisk #Wegovy
The issuer is solely responsible for the content of this announcement.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs around 77,400 people in 80 countries and markets its products in around 170 countries. In Singapore, Novo Nordisk has been present since 1997 and has approximately 100 employees.
For more information, visit novonordisk.sg
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
10 hours ago
- The Sun
Alarming rise in NCD cases among Malaysians, 19-year-old suffers heart attack
KANGAR: Non-communicable diseases (NCDs) among Malaysians have reached an alarming level, with the youngest recorded heart attack case at the National Heart Institute (IJN) involving a 19-year-old patient. Health Minister Datuk Seri Dr Dzulkefly Ahmad stated that his ministry will address the issue aggressively. He urged Malaysians to adopt a healthy lifestyle, including regular exercise and a balanced diet. High blood pressure, high cholesterol, diabetes, and obesity are the main factors leading to heart attacks, which can be silent killers if ignored. 'According to the findings of the National Health Mobility Survey 2023, one in three Malaysians suffers from hypertension and high cholesterol,' he said. He added that one in six Malaysians suffers from diabetes, while nearly 54 per cent are overweight or obese. 'We are concerned about non-communicable diseases, which are the leading cause of death, namely heart attacks,' he said at a press conference after the opening ceremony of the Karnival Sihat Milik Semua at Dewan 2020. The event was officiated by the Raja Muda of Perlis, Tuanku Syed Faizuddin Putra Jamalullail. Also present was the Raja Puan Muda of Perlis, Tuanku Dr. Hajah Lailatul Shahreen Akashah Khalil. The two-day carnival is part of the Silver Jubilee celebration marking the 25th year of the reign of the Raja of Perlis, Tuanku Syed Sirajuddin Jamalullail. Dzulkefly also highlighted chronic diseases such as lung disease caused by smoking, including COPD, asthma, and lung cancer. 'After heart attacks, the second non-communicable disease is cancer, but lung disease can also be a major killer,' he said. He warned that lung disease could surpass heart attacks if not addressed, particularly due to smoking-related illnesses. Malaysia spends approximately RM64.3 billion annually on NCD treatment, based on WHO data. - Bernama
New Straits Times
12 hours ago
- New Straits Times
Tax cigarettes higher until they smoke no more, say academics
KUALA LUMPUR: Academics have asked the government to tax cigarettes until they cost at least RM25 per pack to discourage smoking in the country. Academy of Professors Malaysia Smoking Cessation Task Force medical and health cluster head Professor Dr Mohamad Haniki Nik Mohamed said the move was in line with WHO's MPOWER strategic plan, which proved effective in reducing smoking among youths and the low-income group. He said the WHO stipulated that tobacco excise tax should account for at least 70 per cent of the retail price, but Malaysia's current rate remained below 60 per cent. "Taxes must be dynamic, reviewed periodically and adjusted according to inflation and rising income levels so that cigarettes do not become more affordable. "The 10-year moratorium granted to the tobacco industry since 2015 should not be repeated," he said. He was commenting on Prime Minister Datuk Seri Anwar Ibrahim's statement regarding the possibility of the government raising tobacco taxes. Haniki said cigarette prices should be raised to a level where smokers could no longer afford to buy them. Higher prices would also make it harder for teenagers to purchase cigarettes. Haniki said global experience showed countries that raised cigarette taxes had not only succeeded in lowering their smoking rates, but also increased national revenue, which could be channelled into public health and education programmes. He added that reducing smoking also brought public health benefits by lowering the incidence of lung cancer, heart disease and chronic obstructive pulmonary disease (COPD). However, he said raising tobacco taxes must be supported by law enforcement, market monitoring and public education to address challenges, such as the smuggling in of cheap cigarettes and lobbying pressure from the tobacco industry. "The smuggling of cheap cigarettes must be tackled decisively. The tobacco industry often uses the outdated excuse that tax hikes will increase cigarette smuggling, when global data proves otherwise if enforcement is done properly," he said. On Thursday, Anwar, who is also the finance minister, confirmed that the government was considering increasing tobacco taxes in the 2026 Budget, which will be tabled in October. He said the current tax rate, at 58.60 per cent of the retail price, has not been reviewed since the last increase in September 2014, and there is no formal mechanism for price adjustments. It is also part of efforts to expand taxes on items that adversely affects health, which include sugar, electronic cigarettes and alcohol, as announced during the tabling of the 13th Malaysia Plan last week.
Free Malaysia Today
15 hours ago
- Free Malaysia Today
74% of cases ‘detected at advanced stage': Malaysia's silent liver cancer crisis
Liver cancer is the eighth most-common cancer in Malaysia, with the second-lowest five-year survival rate of just 12.8%. (Envato Elements pic) KUALA LUMPUR : Hepatitis B is still endemic in Malaysia, while over 21.3% of the population is classified as obese. Both of these are key causes of metabolic dysfunction-associated fatty liver disease, which is putting more and more Malaysians at risk of liver cancer Hepatitis B is still endemic in Malaysia, while over 21.3% of the population is classified as obese. Both of these are key causes of metabolic dysfunction-associated fatty liver disease, which is putting more and more Malaysians at risk of Alarmingly, many cases of liver cancer go undetected until the disease is in late stages. Consultant general, hepatobiliary pancreatic and liver surgeon Dr Johann Faizal Khan said one of the biggest barriers to improving liver cancer outcomes is the lack of effective public screening programmes. 'While high-risk individuals such as those with liver cirrhosis and chronic viral hepatitis are screened, patients who appear relatively healthy may not realise they have either of these diseases,' he said. This issue is not unique to Malaysia: it reflects a global trend, with healthcare institutions now dealing with the long-term effects of undiagnosed or untreated chronic liver conditions. According to the health ministry, liver cancer, especially hepatocellular carcinoma, remains one of the leading causes of premature death in Malaysia. It is the eighth most-common cancer in Malaysia – and has the second-lowest five-year survival rate among major cancers, at just 12.8%. Alarmingly, 74% of cases are diagnosed at the most advanced stage (stage four), where treatment options are limited and outcomes significantly poorer. Dr Johan Faizal Khan. 'The absence of early symptoms should not be mistaken for an assurance of good health. Many individuals who do not drink alcohol or engage in what are typically considered 'high-risk' behaviours assume they are not at risk. 'In reality, liver cancer can develop silently, without any warning signs,' said Johann, who advocates for regular screenings regardless of perceived health status, as early detection remains the most effective way to improve outcomes. While late detection remains a challenge, a range of innovative treatment options are available to give renewed hope to patients. Minimally invasive procedures, such as ablation therapies, offer a viable alternative to open surgery by reducing surgical trauma, blood loss, and recovery time. 'However, not all tumours are suitable for minimally invasive approaches. Larger tumours or those requiring complex reconstructions may still necessitate traditional open surgery, especially when complete resection – the removal of all traces of cancer – is the goal,' Johann noted. Treatments for liver cancer are guided by a personalised approach, with emphasis on tailoring care to each patient. (Envato Elements pic) In such cases, a partial hepatectomy may be performed to surgically remove the cancerous portion of the liver, allowing the liver to regenerate post-surgery. For patients with more extensive liver damage, a transplant may be required, involving the replacement of the entire diseased liver with a healthy donor organ. While each methods carries its own set of risks, Johann stressed that they do not compete as treatments are guided by a personalised approach, with care and precision medication tailored to each patient. Even after successful treatment, however, patients with underlying conditions such as chronic viral hepatitis, liver fibrosis or cirrhosis remain at lifelong risk. While treatment can halt progression, continued surveillance is critical to detect recurrence early. Equally important is the patient's role in maintaining liver health. Follow-up care goes beyond medical appointments, with patients strongly advised to adopt healthier lifestyle habits, including consuming a balanced diet, and avoiding alcohol, smoking and unregulated traditional medicine – all of which play a critical role in supporting long-term liver health and recovery. 'Empowering patients with the knowledge and tools to take charge of their liver health will be just as critical as medical treatment in shaping long-term outcomes,' Johann concluded.
